Welcome Letter ............................................................................................................................................................ 2
About the Kidney Cancer Association....................................................................................................................... 3
Continuing Medical Education Information ............................................................................................................ 10
Agenda ........................................................................................................................................................................ 16
Faculty ........................................................................................................................................................................ 20
Poster Listings ........................................................................................................................................................... 27
Sponsors ...................................................................................................................................................................... 31

We encourage all attendees to share their IKCS experience on social media. Make sure to add the hashtag #IKCS2021 and tag @KidneyCancer in all your posts!
Welcome Letter

We are pleased to welcome you to the 2021 IKCS: North America!

This year, we are very grateful to be together in-person once again in Austin, Texas for an exciting program that showcases the best in kidney cancer research and discovery. We also welcome those who join us virtually from all over the US and the world so we may exchange ideas that will direct the future of kidney cancer research.

This year we are honored to feature the Nobel Prize-winning immunologist Dr. James P. Allison of the MD Anderson Cancer Center as our IKCS 2021 keynote speaker.

Make sure to spend time in the exhibit hall, network with fellow attendees both in-person and virtually (use the official Twitter hashtag: #IKCS2021), and don’t forget to collect your CME credits.

Our deepest gratitude to those who worked diligently to craft a dynamic event while prioritizing everyone’s health and safety by putting comprehensive COVID-19 safety protocols in place. Among those we wish to thank are:

- Our presenters and panelists for sharing their expertise and insights;
- Our sponsors, exhibitors, and attendees, whose support made IKCS 2021 possible;
- Our Scientific Program Planning Committee – Co-Chairs Chung-Han Lee, MD, PhD and Eric A. Singer, MD, MA, MS, FACS; Matthew T. Campbell, MD, MS; Vitaly Margulis, MD; Brad McGregor, MD; Brian Rini, MD; Laura Wood, RN, MSN, OCN; Tian Zhang, MD.

These are complex and evolving times in healthcare – and in cancer care particularly – and there are not enough words to honor your service to the kidney cancer community. It’s an inspiration and we are proud to support you and help forge the paths to unlocking the cure for kidney cancer. Have a wonderful IKCS 2021!

Sincerely,

Gretchen E. Vaughan
President and CEO
Kidney Cancer Association

Christopher G. Wood, MD, FACS
Chairman, Board of Directors
Kidney Cancer Association

Bradley C. Leibovich, MD
Chair, Medical Steering Committee
Kidney Cancer Association

KIDNEY CANCER ASSOCIATION
9450 SW Gemini Drive #38269
Beaverton, OR 97008-7105
P 847-332-1051
Toll Free: 800-850-9132
office@kidneycancer.org

PRESIDENT AND CEO
Gretchen E. Vaughan

CHIEF ADVANCEMENT OFFICER
Kendall Monroe

MEDICAL DIRECTOR
Sallie McAdoo, MS, CGC

BOARD OF DIRECTORS
Christopher G. Wood, MD, FACS, Chairperson
Craig DePriester, Vice Chairperson
Noah Buntman, Treasurer
Jamie Graves, Secretary
Lisa Alderson
Ronald M. Bukowski, MD
Tessa Churchill, MD, MBA
Bradley C. Leibovich, MD
Ryan Natzke
Eric Perakslis
David Perry, Esq.
Shelley Robson
Nicholas J. Vogelzang, MD
Laura Wood, RN, MSN, OCN
Ruben Ybarra

MEDICAL STEERING COMMITTEE
Bradley C. Leibovich, MD, Chairperson
Brian Rini, MD, Vice-Chairperson
Laurence Albigeres, MD, PhD
Axel Bex, MD, PhD
Ronald M. Bukowski, MD (Emeritus)
James Hsieh, MD, PhD
Jose A. Karam, MD, FACS
Chung-Han Lee, MD, PhD
Pavlos Msaouel, MD, PhD
Sumanta Kumar Pal, MD
W. Kimryn Rathmell, MD, PhD
Walter M. Stadler, MD, FACP (Emeritus)
Nizar M. Tannir, MD, FACP (Emeritus)
Christopher G. Wood, MD, FACS
Tian Zhang, MD
ABOUT THE KIDNEY CANCER ASSOCIATION

The Kidney Cancer Association was founded in 1990 by Eugene P. Schonfeld and a small group of patients and doctors in Chicago, Illinois and has grown into an international non-profit organization. The KCA promotes scientific advances through two annual research symposiums and a robust grant program, participates in legislative advocacy, and seeks to be a source of education and resources for patients, caregivers, and anyone impacted by kidney cancer.

Our vision is to be the universal leader in finding the cure for kidney cancer.

Our mission is to be a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education.

One of the Association’s most important contributions is its support of the physicians and nurses who care for kidney cancer patients. Through our educational activities we help ensure that the latest medical advances and best practices are shared. Our global medical conferences bring together the world’s leading technology and treatment options.

—Gretchen E. Vaughan, President and CEO, Kidney Cancer Association

MAIL DONATIONS TO:

Please send donations to our secure lock-box:
Kidney Cancer Association
PO Box 676226
Dallas, TX 75267-6226
Tel: 847-332-1051
office@kidneycancer.org
See you in Austin, TX, USA for 2022 IKCS: North America

SAVE THE DATE
November 4 – 5, 2022
In-person with virtual streaming

Learn more at KCAMEETINGS.ORG
Stay up to date with
INLYTA® (axitinib) + pembrolizumab data

See the data here

Please see full Prescribing Information at INLYTAhcp.com.
BOARD OF DIRECTORS

Lisa Alderson
Ronald M. Bukowski, MD
Noah Buntman (Treasurer)
Tessa Churchill, MD, MBA
Craig DePriester (Vice-Chair)
Jamie Graves (Secretary)
Bradley C. Leibovich, MD
Ryan Natzke
Eric Perakslis

David Perry, Esq.
Shelley Robson
Gretchen E. Vaughan
Nicholas J. Vogelzang, MD
Christopher G. Wood, MD, FACS (Chair)
Laura Wood, RN, MSN, OCN
Ruben Ybarra

MEDICAL STEERING COMMITTEE

Bradley C. Leibovich, MD, Chair
Brian Rini, MD, Vice-Chair
Laurence Albiges, MD, PhD
Axel Bex, MD, PhD
Ronald M. Bukowski, MD (Emeritus)
James Hsieh, MD, PhD
Jose A. Karam, MD, FACS
Chung-Han Lee, MD, PhD
Pavlos Msaouel, MD, PhD
Sumanta Kumar Pal, MD
W. Kimryn Rathmell, MD, PhD
Walter M. Stadler, MD, FACP (Emeritus)
Nizar M. Tannir, MD, FACP (Emeritus)
Christopher G. Wood, MD, FACS
Tian Zhang, MD

CLINICAL ADVISORY BOARD

Nancy Ainslie, RN, BSN
Julia Batten, APRN, MSN, MPH
Nina Decker, MSW, LCSW
Patricia Fisher, RN, MSN, OCN
Jan Jackson, RN
Kiran Kehoe, RN, BSN, CCRN
Zita Lim, PA-C
Nancy Moldawer, RN, MSN, Co-Chair
Kathryn Nelson, RN
Virginia J. Seery, MSN, RN, ANP-BC
Meghara Walsh, RN, BSN
Laura Wood, RN, MSN, OCN, Co-Chair

PATIENT & CAREGIVER ADVISORY COUNCIL

Kathleen Campbell
Steven Edwards
John Ferrell
Bruce Hill
Susan Hill
Vineeta Hiranandani
Ritchie Johnson
Benjamin Lundin
Deb Maskens
Ryan Natzke, Chair
Marissa Willis
Salima Witt
Peggy Zuckerman

IKCS: NORTH AMERICA 2021
SCIENTIFIC PLANNING

Matthew T. Campbell, MD, MS
Chung-Han Lee, MD, PhD, Co-Chair
Vitaly Margulis, MD
Brad McGregor, MD
Brian Rini, MD
Eric A. Singer, MD, MA, MS, FACS, Co-Chair
Laura Wood, RN, MSN, OCN
Tian Zhang, MD
The passings of Gisela and Jon are enormous losses to both their families and our Exelixis team.

Gisela and Jon both possessed an unwavering dedication to improving care and outcomes for patients who are battling cancer and will be sorely missed by their families, friends, and colleagues.
The passings of Gisela and Jon are enormous losses to both their families and our Exelixis team. Gisela and Jon both possessed an unwavering dedication to improving care and outcomes for patients who are battling cancer and will be sorely missed by their families, friends, and colleagues.

A donation can be made in honor of Gisela and Jon by visiting FamilyReach.org

Help support families impacted by cancer by donating to Family Reach®.

The organization delivers financial education, financial planning assistance, resource navigation, and emergency relief funds to patients and caregivers who are facing a cancer diagnosis, so that no family is forced to choose between their health and their home.

Team Exelixis
Free Continuing Medical Education (CME) sessions for healthcare professionals interested in advancing their clinical knowledge in kidney cancer.

Learn more at kidneycancer.org/cme-programming

JUST DIAGNOSED TOOLKIT
Access the toolkit online at kidneycancer.org/just-diagnosed

PATIENT NAVIGATOR PROGRAM
Our Patient Liaison can help locate financial assistance, local support services, or a kidney cancer specialist.

Contact the Patient Liaison and/or request a printed toolkit:
1-800-544-3KCA | patient@kidneycancer.org
TARGET AUDIENCE
This educational activity is intended for medical oncologists and urologists who treat patients with kidney cancer. Fellows, trainees, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of kidney cancer are invited to participate.

STATEMENT OF NEED
Education and interaction surrounding the space of renal cell carcinoma are paramount to improving patient care. This program is targeted to physicians, advocates and researchers to help promote learning and collaboration for advancement in the renal cancer space.

EDUCATIONAL ACTIVITY LEARNING OBJECTIVES
Upon completion of this course, the participants should be able to:

• Characterize the various therapies currently available for locally advanced and metastatic renal cell carcinoma
• Identify the novel approaches to non-clear RCC patient management
• Understand the role of the tumor microenvironment in kidney cancer
• Discuss how to design biomarker driven clinical trials in kidney cancer

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the Kidney Cancer Association. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
Physicians:
The France Foundation designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ETHICS
This course has been designated for 0.75 credit(s) of education in medical ethics and/or professional responsibility.
CONTINUING MEDICAL EDUCATION INFORMATION

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT

1. Review the activity objectives and CME/CE information.

2. Participate in the CME/CE activity.

3. TO CLAIM CREDIT: Go to the web portal CreditFF.com/IKCS. Complete the evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.

4. If you are requesting educational credits or a certificate of participation, your certificate will be available for download.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the Kidney Cancer Association (KCA) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and KCA resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and KCA seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and KCA are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

ACTIVITY STAFF DISCLOSURES

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at The Kidney Cancer Association who control content have no relevant financial relationships to disclose.

FACULTY DISCLOSURES

The following faculty report that they have relevant financial relationships to disclose:

- **James P. Allison, PhD** has a consulting or stock ownership or advisory board relationship with Achelois, Adaptive Biotechnologies, Apricity, BioAtla, BioNTech, Candel Therapeutics, Cordik, Dragonfly, Earli, Enable Medicine, Hummingbird, ImaginAb, Jounce, Lava Therapeutics, Lytix, Marker, PBM Capital, Phenomic AI, Polaris Pharma, Time Bioventures, Trained Therapeutix, Two Bear Capital, Venn Biosciences.

- **Ronald S. Boris, MD, MS** has a non-CE consulting relationship with Tymora Analytical.

- **James Brugarolas, MD, PhD** had a non-CE consulting relationship with Arrowhead that ended in 2020, and non-CE consulting relationships with Eisai, Johnson & Johnson, and Darmouth that end in 2021. He also participated in a non-CE speaker bureau as an advisory board member in 2020 for Callithera.
CONTINUING MEDICAL EDUCATION INFORMATION

FACULTY DISCLOSURES

• Matthew T. Campbell, MD, MS has a non-CE consulting relationship with Astellas, Seagen, Eisai, Exelixis, Pfizer, AstraZeneca, Apricity Health, and AX Dev; he has a contract research relationship with Janssen, Pfizer, EMD Serono, Exelixis, AstraZeneca, Apricity Health, and Aravive; and non-branded medical education programs with Bristol Myers-Squibb, Merck, Pfizer, and Roche.

• Toni Choueiri, MD has non-CE consulting relationships with AstraZeneca, Aveo, Bayer, Bristol Myers-Squibb, Eisai, Exelixis, GlaxoSmithKline, IQVA, Ipsen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi / Aventis, Takeda, and Tempest.

• Nazli Dizman, MD has a non-CE consulting relationship with Vivreon Gastroscience Inc.

• Darren R. Feldman, MD has contract research relationships with Astellas, Decibel, and Novartis, and royalty with UpToDate.

• Kun-Liang Guan, PhD has a non-CE consulting relationship with Vivace, OncoC4, Cullgen, and Meton; received a royalty from the University of Michigan in 2021, cash from Oncolmmune when the company was sold in 2020; owns stocks of the commercial entity from OncoC4, Vivace, and Meton.

• Kirsten L. Greene, MD owns stocks of the commercial entity with Doximity.

• Naomi Haas, MD has served on the advisory boards for Exelixis, Eisai, and Aveo.

• A. Ari Hakimi, MD had a non-CE consulting relationship with Merck.

• Raquibul Hannan, MD, PhD has an ongoing contract research relationship with Prometheus Laboratories.

• Bruce A. Hill has a non-CE consulting relationship with Merck & Co., Inc.

• Jose Antonio Kareem, MD has a non-CE consulting relationship with Merck, Pfizer, Johnson & Johnson; has participated in a non-CE speakers bureau with Roche/Genentech, Mirati, Merck; and owns stocks of the commercial entity of MedTek, ROM Technologies.

• Hyung L. Kim, MD has a receipt of intellectual property rights with Crown Bioscience.

• Ritesh R. Kotecha, MD has a contract research relationship with Pfizer, Takeda, and Allogene.

• Primo Nery Lara Jr., MD has contract research relationships with Janssen, Merck, Incyte, Pharmacyclics, and Taiho.

• Chung-Han Lee, MD, PhD has non-CE consulting relationships with BMS, Eisai, Exelixis, Intellisphere, Merck, Pfizer, Research to Practice

• Sandy Ting Liu, MD has a non-CE speakers bureau relationship with Exelixis, EMD Serono, Seattle Genetics, and Eisai.

• Jodi K. Maranchie, MD, PhD had non-CE consulting relationships with Merck, completed on 3/25/21, and Sanofi, completed on 9/16/20. She currently does editorial services for Elsevier.

• Deborah Maskens has a non-CE consulting relationship with BMS and Merck.

• Bradley McGregor, MD had non-CE consulting relationships that ended in 2020 with Pfizer/EMD Serono, Eisai, Dendreon, Exelixis, Calithera, and BMS. He participates in research funding to institutions from BMS, Exelixis, Seattle Genetics, Calithera, and Genentech.
FACULTY DISCLOSURES

- **Pavlos Msaouel, MD, PhD** has received honoraria for service on Scientific Advisory Board for Mirati Therapeutics, Exelixis, and BMS, consulting for Axiom Healthcare Strategies, non-branded educational programs supported by Exelixis and Pfizer, and research funding for clinical trials from Takeda, BMS, Mirati Therapeutics, Gateway for Cancer Research, and UT MD Anderson Cancer Center. Dr. Msaouel is supported by a Young Investigator Award by the Kidney Cancer Association, a Career Development Award by the American Society of Clinical Oncology, by a Concept Award by the United States Department of Defense, by the MD Anderson Khalifa Scholar Award, by Bristol-Myers Squibb, by Mirati Therapeutics, and by Takeda.

- **Ryan Natzke** has a salary or employment relationship (does not include small non-employed consulting arrangements with Marshfield Clinic Health System.

- **Moshe C. Ornstein, MD, MA** has non-CE consulting relationships with BMS, Pfizer, Exelixis, Eisai, and Meton that end in 2021; non-CE speaker bureau relationships with BMS and Exelixis that ended in 2019; and an ongoing contract research relationship with Pfizer and BMS.

- **Sumanta Kumar Pal, MD** has a non-CE consulting relationship with F. Hoffmann La Roche, contract research relationship with Eisai, Genentech, Roche, and Exelixis, and travel, accommodation expenses with Genentech and Seattle Genetics.

- **Ivan Pedrosa, MD, PhD** owns stocks of the commercial entity with Health Tech International. His non-CE consulting advisory board relationship with Merck ended on 3/2/2021.

- **Sarah P. Psutka, MD, MSc** had a contract research relationship that ended in October of 2020. She developed patient-educational materials on bladder cancer regarding shared decision-making for PRIME Education Inc. and ran a focus group utilizing these materials.

- **W. Kimryn Rathmell, MD, PhD** has the following royalties: ClearCode34 Risk prediction biomarker for kidney cancer, and hERV 3-2 expression as a biomarker or response to immunotherapy.

- **Brian Rini, MD** has non-CE consulting relationships with BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GSK, Shionogi, and Eisai. He has contract research relationships with Pfizer, Hoffman-LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, and Exelixis.

- **Tracy L. Rose, MD, MPH** has a contract research relationship with GeneCentric Therapeutics, Genentech/Hoffmann-La Roche, Bristol-Myers Squibb, and Merck.

- **Biren Saraiya, MD** has a non-CE consulting relationship with Eisai Corp.

- **Brian Shuch, MD** has a non-CE consulting relationship with J&J, Merck, BMS, Veracyte, Genentech, and Histosonics.

- **Eric A. Singer, MD, MA, MS, FACS** has a non-CE consulting relationship with J&J, Merck, and Vyriad. He also had a contract research relationship with Astellas/Medivation that ended in 2020.
CONTINUING MEDICAL EDUCATION INFORMATION

FACULTY DISCLOSURES

• Randy Sweis, MD has a non-CE consulting relationship with Aduro, Astellas, AstraZeneca, BMS, EMD Serono, Exelixis, Eisai, Janssen, Mirati, Pfizer, and Seattle Genetics. Dr. Sweis has a contract research relationship with Abbvie, Aduro, Bayer, BMS, CytomX, Eisai, Eli Lilly, Genentech/Roche, Immunocore, and Novartis. He has a receipt of the following patent: “Neoantigens in Cancer” Patent Pub. #WO/2020/227233 A2/ PCT/US2020/031357.

• Nizar M. Tannir, MD, FACP has a non-CE consulting relationship with Oncorena, Merck, Eisai, DEKA Biosciences, Calithera, BMS, and Neoleukin Corporation; contract research relationship with Bristol-Myers Squibb, Nektar Therapeutics, Calithera Bioscience, and Arrowhead Pharmaceutical, Inc.

• Ulka Nitin Vaishampayan, MBBS has non-CE consulting relationships with BMS, Exelixis, Merck, Eisai, Pfizer, EMD Serono, Alkermes, AAA, and Bayer; non-CE speakers bureau relationships with Exelixis, Bayer, BMS, and Sanofi; contract research with Merck, BMS, and Astellas.

• Martin H. Voss, MD has non-CE consulting relationships with Aveo, Eisai, Exelixis, Merck, Calithera, and Genentech, and contract research relationships with Pfizer and BMS.

• Christopher G. Wood, MD, FACS has a non-CE consulting and non-CE speakers bureau relationship with Pfizer, as well as a contract research relationship with Mirati and Colimmune.

• Jeff Yorio, MD has a non-CE consulting relationship with Bristol-Myers Squibb.

• Tian Zhang, MD is a principal investigator or researcher for Genentech/Roche, Novartis, Merrimack, Abbvie/StemCentrx, Merck, Regeneron, Mirati Therapeutics, Janssen, Astra Zeneca, Pfizer, OmniSeq, Personal Genome Diagnostics, SeaGen and Astellas. Dr. Zhang is on the advisory boards for Genentech/Roche, Merck, Exelixis, Sanofi-Aventis, Janssen, Astra Zeneca, Pfizer, Amgen, BMS, Dendreon, SeaGen, and Eisai. Speaker relationship with Genomic Health, and a consultant relationship with Merck and Pfizer.

INSTRUCTIONS FOR ACCESSING THE IKCS 2021 CONFERENCE APP

FOR MOBILE

Go to http://eventmobi.com/app/ikcs2021 or follow the following steps:
1. Go to app store and look for EventMobi App
2. Download the App
3. Search within EventMobi for the IKCS2021 event
4. Enter email address and create password

FOR PC
1. Go to http://eventmobi.com/ikcs2021
2. Enter email address and create password

If you have attended an event on the EventMobi Platform in the past with your current email address, the password would be the same as before.
CONTINUING MEDICAL EDUCATION INFORMATION

The faculty listed below report that they have no relevant financial relationships to disclose:

- Divya Bezwada
- Maria Carlo, MD
- Steven Lee Chang, MD, MS
- Stephen H. Culp, MD
- Lola Fashoyin-Aje, MD, MPH
- Saeed Hassanpour, PhD
- Eric Kauffman, MD
- Akash Kaushik, MS, PhD
- Deborah R. Kaye, MD, MS
- Brian Lane, MD, PhD
- Bradley C. Leibovich, MD
- Amy N. Luckenbaugh, MD
- Amrita Mangalvedhekar Nargund, PhD
- Vitaly Margulis, MD
- Theresa J. Miller, PhD
- Krishnendu Pal, PhD
- Sunil Sudarshan, MD
- Gretchen Vaughan
- Christopher Weight, MD, MSc

The faculty listed below will provide their disclosure to learners at the beginning of their presentation.

- Mohamad Allaf, MD
- Pedro C. Barata, MD, MSc
- Sari Khaleel, MD
- Nita M. Lowey
- Viraj Master, MD, PhD, FACS
- Charlotte Spencer, MBBS, MRCP

These relevant conflicts of interest have been mitigated through content reviews.

DISCLOSURE OF UNLABELED USE

TFF and KCA require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that
is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and KCA do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The France Foundation and the Kidney Cancer Association present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the Kidney Cancer Association assume no liability for the information herein.

Note: Missing disclosures were not submitted in time for printing. Their disclosures will be available during their session talks.

## Sponsored Symposia*

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, November 4</td>
<td>6:00 PM - 7:00 PM</td>
<td>Merck: Recent Developments for Adult Patients With Certain VHL-Associated Tumors - Webcast</td>
</tr>
<tr>
<td>Thursday, November 4</td>
<td>8:00 PM - 9:00 PM</td>
<td>Peerview: Selecting and Sequencing Targeted and Immunotherapy Regimens for Patients With RCC: How Will the Latest Evidence Impact Treatment Decisions for My Patients?</td>
</tr>
<tr>
<td>Friday, November 5</td>
<td>6:30 AM - 7:30 AM</td>
<td>Eisai: A First-Line Treatment Option for Your Patients with Advanced Renal Cell Carcinoma</td>
</tr>
<tr>
<td>Friday, November 5</td>
<td>12:45 PM - 1:30 PM</td>
<td>Exelixis: CABOMETYX® + OPDIVO®: A Combination Treatment for 1L Patients With Advanced Renal Cell Carcinoma</td>
</tr>
<tr>
<td>Saturday, November 6</td>
<td>6:30 AM - 7:30 AM</td>
<td>Aveo: A Treatment Option for Relapsed/Refractory Renal Cell Carcinoma After 2 or More Prior Systemic Therapies</td>
</tr>
<tr>
<td>Saturday, November 6</td>
<td>12:10 PM - 12:55 PM</td>
<td>Pfizer: From Patient to Practice: Overview of the efficacy, safety profile, dosing, and therapy management for a combination regimen in first-line advanced RCC</td>
</tr>
</tbody>
</table>

*All symposia are located in Zilker 2-4. Meals will be provided by the KCA.

** Peerview is the accredited provider for this CME sponsored symposium.
## Sessions

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 AM</td>
<td>A promotional presentation sponsored by Eisai Inc.</td>
</tr>
</tbody>
</table>

### Break

**7:30 AM**

### CME SESSIONS

**Welcome**

**8:00 AM**

**Co-chairs:**

- Chung-Han (Joe) Lee, MD, PhD
- Eric A. Singer, MD, MA, MS, FACS

#### Session 1: Woodfire

**8:10 AM**

**Session 2: Multimodality Perspectives on Clinical Trial Development**

**9:10 AM**

**Tian Zhang, MD**

**Deborah R. Kaye, MD, MSc**

**Health Equity in Clinical Trials**

**9:10 AM**

**Lola Fashoyin-Aje, MD, MPH**

**Enhancing Patient-centered Care in Systemic Therapy and Clinical Trials**

**9:25 AM**

**Biren Saraiya, MD**

**The Future of Neoadjuvant Trials in Locally Advanced RCC (Panel)**

**9:45 AM**

**Jose A. Karam, MD**

**Viraj Master, MD, PhD, FACS**

**Primo Nery Lara, Jr., MD**

**Naomi Haas, MD**

**Deb Maskens**

**Q+A**

**10:15 AM**

**Break**

**10:30 AM**

#### Session 3: Non-clear cell RCC

**10:45 AM**

**Phenotypic Characterization of Renal Masses - The Virtual Biopsy**

**10:45 AM**

**Ivan Pedrosa, MD, PhD**

**Surgical Management**

**11:00 AM**

**Ronald S. Boris, MD, MS**

**Use of AI Deep Learning in Histologic Classification**

**11:15 AM**

**Saeed Hassanpour, PhD**

**Role of NF2 in Tumorigenesis**

**11:30 AM**

**Kun-Liang Guan, PhD**

**Systemic Therapy for Non-Clear Cell: Recent and Future Studies**

**11:45 AM**

**Bradley McGregor, MD**

**Q+A**

**12:00 PM**

**Break**

**12:15 PM**

#### Non-CME Symposium

**CABOMETYX® + OPDIVO®: A Combination Treatment for 1L Patients With Advanced Renal Cell Carcinoma**

**12:45 PM**

**Sponsored by Exelixis**

**Break**

**1:30 PM**

#### Session 4: Keynote Lecture

**2:00 PM**

**Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms**

**James P. Allison, PhD**

#### Session 5: Translational Cancer Insights

**3:00 PM**

**Tracy L. Rose, MD, MPH**

**Hyung L. Kim, MD**

**Immunologic Consequences of Obesity in ccRCC**

**3:00 PM**

**A. Ari Hakimi, MD**

**Role of the Microbiome in Cancer**

**3:15 PM**

**Nazli Dizman, MD**

**Metabolomics in RCC**

**3:30 PM**

**Vitaly Margulis, MD**
<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novel Immunotherapy Targets</td>
<td>3:45 PM</td>
<td>Moshe Ornstein, MD, MA</td>
</tr>
<tr>
<td>Assessing Human Kidney Cancer Metabolism with Intraoperative Isotope Tracing</td>
<td>4:00 PM</td>
<td>Divya Bezvada</td>
</tr>
<tr>
<td>Q+A</td>
<td>4:15 PM</td>
<td></td>
</tr>
<tr>
<td>Break</td>
<td>4:30 PM</td>
<td></td>
</tr>
<tr>
<td>Session 6: Mentoring The Next Generation Roundtable and Networking Hot Topics</td>
<td>4:50 PM</td>
<td>Sandy Ting Liu, MD</td>
</tr>
<tr>
<td>Kidney Cancer Academy</td>
<td>4:50 PM</td>
<td>Brian Rini, MD</td>
</tr>
<tr>
<td>Evaluating HLA Class II Evolutionary Divergence as an Immunotherapy Specific Kidney Cancer Biomarker</td>
<td>4:55 PM</td>
<td>Ritesh Kotecha, MD</td>
</tr>
<tr>
<td>System Characterization of Kidney Cancer Tumor Suppressors in Modulating Metastasis and Response to Immunotherapy</td>
<td>5:00 PM</td>
<td>Amrita M. Mangalvedhekar, PhD</td>
</tr>
<tr>
<td>Overriding Radiation Therapy Resistance and Enhancing the Abscopal Effect in Renal Cancer</td>
<td>5:05 PM</td>
<td>Krishnendu Pal, PhD</td>
</tr>
<tr>
<td>Mentorship Roundtable</td>
<td>5:10 PM</td>
<td></td>
</tr>
<tr>
<td>* Medical Oncology</td>
<td></td>
<td>Sumanta Kumar Pal, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Brian Rini, MD</td>
</tr>
<tr>
<td>* Urology</td>
<td></td>
<td>Bradley C. Leibovich, MD</td>
</tr>
<tr>
<td>* Translational Researcher</td>
<td></td>
<td>James Brugarolas, MD, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>W. Kimryn Rathmell, MD, PHD</td>
</tr>
<tr>
<td>Networking Hot Topics</td>
<td>5:35 PM</td>
<td></td>
</tr>
<tr>
<td>* Community Oncology</td>
<td></td>
<td>Jeff Yorio, MD</td>
</tr>
<tr>
<td>* 1st Clinical Trial</td>
<td></td>
<td>Brian Shuch, MD</td>
</tr>
<tr>
<td>* Becoming Independent/Funding</td>
<td></td>
<td>W. Kimryn Rathmell, MD, PHD</td>
</tr>
<tr>
<td>* Societies and Advocacy</td>
<td></td>
<td>Nizar M. Tannir, MD, FACP</td>
</tr>
</tbody>
</table>
| Poster Walk                                                           | 6:00–7:00 PM | Eric Kauffman, MD  
|                                                                      |         | Ritesh R. Kotecha, MD &  
|                                                                      |         | Nizar M. Tannir, MD, FACP &  
<p>|                                                                      |         | Stephen H. Culp, MD                                            |
| Reception                                                             | 6:00–7:30 PM |                                                  |</p>
<table>
<thead>
<tr>
<th>Sessions</th>
<th>Time</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-CME Symposium</td>
<td>6:30 AM</td>
<td>Sponsored by Aveo</td>
</tr>
<tr>
<td>A Treatment Option for Relapsed/Refractory Renal Cell Carcinoma After 2 or More Prior Systemic Therapies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Break</td>
<td>7:30 AM</td>
<td></td>
</tr>
<tr>
<td>CME SESSIONS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Welcome</td>
<td>8:00 AM</td>
<td>Co-chairs: Chung-Han (Joe) Lee, MD, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eric A. Singer, MD, MA, MS, FACS</td>
</tr>
<tr>
<td>Session 7: The State of Adjuvant Therapy and How to Move Forward</td>
<td>8:05 AM</td>
<td>Randy Sweis, MD</td>
</tr>
<tr>
<td>Future of Adjuvant Therapy in RCC</td>
<td>8:05 AM</td>
<td>Toni Choueiri, MD</td>
</tr>
<tr>
<td>Advanced Kidney Cancer Management in the Emerging Era of Adjuvant Therapy IO Case Discussion</td>
<td>8:30 AM</td>
<td>Martin H. Voss, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Viraj Master, MD, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Brian Shuch, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Biren Saraiya, MD</td>
</tr>
<tr>
<td>Q+A</td>
<td>9:05 AM</td>
<td></td>
</tr>
<tr>
<td>Session 8: Advocacy, Funding, and the Patient Experience</td>
<td>9:25 AM</td>
<td>Matthew T. Campbell, MD, MS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kirsten L. Greene, MD</td>
</tr>
<tr>
<td>KCA Programmatic Initiatives</td>
<td>9:25 AM</td>
<td>Sallie McAdoo, MS, CGC</td>
</tr>
<tr>
<td>CDMRP</td>
<td>9:35 AM</td>
<td>Theresa J. Miller, PhD</td>
</tr>
<tr>
<td>Legislative Advocacy Round Table</td>
<td>9:45 AM</td>
<td>Bruce Hill</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ryan Natzke</td>
</tr>
<tr>
<td>Q+A</td>
<td>10:05 AM</td>
<td></td>
</tr>
<tr>
<td>Break</td>
<td>10:20 AM</td>
<td></td>
</tr>
<tr>
<td>Session 9: Award Lecture</td>
<td>10:40 AM</td>
<td>Bradley C. Leibovich, MD</td>
</tr>
<tr>
<td>Andrew C. Novick Award Lecture</td>
<td>10:40 AM</td>
<td>Brian Lane, MD, PhD</td>
</tr>
<tr>
<td>Break</td>
<td>11:40 AM</td>
<td></td>
</tr>
<tr>
<td>Non-CME Symposium</td>
<td>12:10 PM</td>
<td>Sponsored by Pfizer</td>
</tr>
<tr>
<td>From Patient to Practice: Overview of the Efficacy, Safety Profile, Dosing, and Therapy Management for a Combination Regimen in First-line Advanced RCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Break</td>
<td>12:55 PM</td>
<td></td>
</tr>
<tr>
<td>Session 10: Top Abstracts</td>
<td>1:25 PM</td>
<td>Darren R. Feldman, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sunil Sudareshan, MD</td>
</tr>
<tr>
<td>Gene Expression Profiling (GEP) of non-clear cell renal cell carcinoma (nccRCC) identifies a unique spectrum of transcriptional signatures with potential clinical relevance</td>
<td>1:25 PM</td>
<td>Pedro C. Barata, MD, MSc</td>
</tr>
<tr>
<td>Outcomes of Cytoreductive Nephrectomy Followed by Active Surveillance in Metastatic Renal Cell Carcinoma</td>
<td>1:32 PM</td>
<td>Sari Khaleel, MD</td>
</tr>
<tr>
<td>Machine learning predicts BAP1/PBRM1 from digital histology in clear cell Renal Cell Carcinoma: TRACERx Renal</td>
<td>1:39 PM</td>
<td>Charlotte Spencer, MBBS, MRCP</td>
</tr>
<tr>
<td>Session 11: Role of Perioperative Therapy in RCC</td>
<td>Time</td>
<td>Speakers</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>--------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Use of AI for RCC Diagnosis of CT Scans</td>
<td>2:10 PM</td>
<td>Christopher Weight, MD, MSc</td>
</tr>
<tr>
<td>Role of IVC Thrombus w/ SBRT; Neoadjuvant SBRT</td>
<td>2:25 PM</td>
<td>Raquibul Hannan, MD, PhD</td>
</tr>
<tr>
<td>Surgical Considerations with Perioperative Therapy</td>
<td>2:40 PM</td>
<td>Mohamad Allaf, MD</td>
</tr>
<tr>
<td>Q+A</td>
<td>2:55 PM</td>
<td></td>
</tr>
<tr>
<td>Thank You and Adjourn</td>
<td>3:10 PM</td>
<td></td>
</tr>
</tbody>
</table>
Mohamad Ezzeddine Allaf, MD  
Executive Vice Chairman,  
Department of Urology  
Professor of Urology  
Johns Hopkins Medical Institute  
Baltimore, MD

James P. Allison, PhD  
Professor and Chair,  
Department of Immunology  
Executive Director,  
Immunotherapy Platform  
The University of Texas MD Anderson Cancer Center  
Houston, TX

Ronald S. Boris, MD, MS  
Associate Professor, Urology  
Indiana University Department of Urology  
Indianapolis, IN

James Brugarolas, MD, PhD  
Professor, Internal Medicine - Hematology/Oncology  
Director, Kidney Cancer Program  
UT Southwestern Medical Center  
Dallas, TX

Matthew T. Campbell, MD, MS  
Assistant Professor, Genitourinary Medical Oncology  
UT MD Anderson Cancer Center  
Houston, TX

Marie Carlo, MD  
Assistant Attending  
Memorial Sloan Kettering Cancer Center  
New York, NY

Steven Lee Chang, MD, MS  
Section Chief of Urologic Oncology  
Brigham and Women’s Hospital  
Co-Director of the Kidney Cancer Center,  
Dana-Farber Cancer Institute  
Co-Director, Combined Harvard Urologic Oncology Fellowship  
Harvard Medical School  
Boston, MA

Toni Choueiri, MD  
Chief Director, Lank Center for Genitourinary Oncology  
Dana-Farber Cancer Institute  
Boston, MA

Stephen H. Culp, MD  
Associate Professor of Urology  
University of Virginia  
Charlottesville, VA
Faculty

Nazli Dizman, MD
Yale School of Medicine
New Haven, CT

Lola Fashoyin-Aje, MD, MPH
Associate Director, Oncology Center of Excellence
Food and Drug Administration,
Oncology Center of Excellence
Silver Spring, MD

Darren R. Feldman, MD
Associate Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY

Kirsten L. Greene, MD
Paul Mellon Professor and Chair
Department of Urology
University of Virginia
Charlottesville, VA

Kun-Liang Guan, PhD
Professor
University of California, San Diego
La Jolla, CA

Naomi B. Haas, MD
Professor of Medicine,
Perelman School of Medicine
Abramson Cancer Center,
University of Pennsylvania
Philadelphia, PA

A. Ari Hakimi, MD
Associate Professor
Memorial Sloan Kettering Cancer Center, Dept of Surgery, Urology Service
New York, NY

Raquibul Hannan, MD, PhD
Associate Professor of Radiation Oncology and Immunology
UT Southwestern Medical Center
Simmons Cancer Center
Dallas, TX

Saeed Hassanpour, PhD
Associate Professor
Departments of Biomedical Data Science, Computer Science, and Epidemiology
Geisel School of Medicine at Dartmouth
Lebanon, NH
Faculty

Bruce Hill
Kidney Cancer Association
Patient-Caregiver Advisory Council
New Paltz, NY

Jose A. Karam, MD, FACS
Associate Professor of Urology and Translational Molecular Pathology
MD Anderson Cancer Center
Houston, TX

Eric Kauffman, MD
Assistant Professor of Oncology
Attending Surgeon, Department of Urology
Roswell Park Comprehensive Cancer Center
Buffalo, NY

Akash Kaushik, MS, PhD
Postdoctoral Researcher
University of Texas Southwestern Medical Center
Dallas, TX

Deborah R. Kaye, MD, MS
Assistant Professor
Duke University
Durham, NC

Hyung L. Kim, MD
Director, Academic Urology Program
Cedars-Sinai Medical Center
Los Angeles, CA

Ritesh R. Kotecha, MD
Assistant Attending
Memorial Sloan Kettering Cancer Center
New York, NY

Brian Lane, MD, PhD
Professor of Surgery
Spectrum Health/Michigan State University College of Human Medicine
Grand Rapids, MI

Primo Nery Lara, Jr., MD
Director
UC Davis Comprehensive Cancer Center
Sacramento, CA
Faculty

Chung-Han Lee, MD, PhD
Medical Oncologist
Memorial Sloan Kettering
Cancer Center
New York, NY

Bradley C. Leibovich, MD
David C. Utsz Professor of Urology
Mayo Clinic College of Medicine
Chair, Department of Urology
Mayo Clinic
Rochester, MN

Sandy Ting Liu, MD
Physician in Oncology
Ronald Reagan UCLA
Santa Monica Medical Center
UCLA Hospital
Providence Tarzana Medical Center
Los Angeles, CA

Amy N. Luckenbaugh, MD
Assistant Professor of Urology
Vanderbilt University Medical Center
Nashville, TN

Jodi K. Maranchie, MD, PhD
Associate Professor of Urology
UPMC
Pittsburgh, PA

Vitaly Margulis, MD
Professor - Urology
UT Southwestern Medical Center - Dallas
Dallas, TX

Deb Maskens
Patient Advocate
Kidney Cancer Association PCAC
Guelph, ON Canada

Viraj Master, MD, PhD, FACS
Professor and Fray F. Marshall Chair in Clinical Urologic Research, Department of Urology
Director of Clinical Research, Department of Urology
Emory University School of Medicine
Director of Integrative Oncology and Survivorship
Winship Cancer Institute of Emory University
Atlanta, GA

Bradley McGregor, MD
Medical Oncologist
Dana Farber Cancer Institute
Boston, MA
Faculty

Theresa J. Miller, PhD
Program Manager
Department of Defense Kidney Cancer Research Program
Fort Detrick, Frederick, MD

Pavlos Msaouel, MD, PhD
Assistant Professor
The University of Texas MD Anderson Cancer Center
Houston, TX

Amrita N. Mangalvedhekar, PhD
Senior Research Scientist, Human Oncology and Pathogenesis Memorial Sloan Kettering Cancer Center
New York, NY

Ryan Natzke
Chief External Affairs Officer
Marshfield Clinic Health System
Marshfield, WI

Moshe C. Ornstein, MD, MA
Genitourinary Medical Oncologist
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH

Sumanta Kumar Pal, MD
Clinical Professor
City of Hope
Duarte, CA

Krishnendu Pal, PhD
Assistant Professor
Mayo Clinic College of Medicine and Science
Jacksonville, FL

Ivan Pedrosa, MD, PhD
Professor of Radiology
Vice-Chair of Research, Department of Radiology
UT Southwestern Medical Center
Dallas, TX

Sarah P. Psutka, MD, MSc
Associate Professor of Urology
University of Washington, Seattle Cancer Care Alliance
Seattle, WA
Faculty

W. Kimryn Rathmell, MD, PhD
Chair, Department of Medicine, VUMC
Physician-in-chief, Vanderbilt University Hospital
Nashville, TN

Brian Rini, MD
Professor of Medicine
Vanderbilt Ingram Cancer Center
Nashville, TN

Tracy L. Rose, MD, MPH
Assistant Professor of Medicine, Division of Oncology
University of North Carolina Chapel Hill, NC

Biren Saraiya, MD
Associate Professor of Medicine
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ

Brian Shuch, MD
Associate Professor of Urology
David Geffen School of Medicine
University of California Los Angeles
Los Angeles, CA

Eric A. Singer, MD, MA, MS, FACS
Associate Chief of Urology and Urologic Oncology
Associate Professor of Surgery and Radiology
Director, Kidney Cancer Program, Rutgers Cancer Institute of New Jersey
Director, Distinction in Bioethics Program, Rutgers Robert Wood Johnson Medical School
Chair, Ethics Committee, Robert Wood Johnson University Hospital
New Brunswick, NJ

Sunil Sudarshan, MD
Professor of Urology
Co-Leader Cancer Biology and Immunology Program
O’Neal Comprehensive Cancer Center
University of Alabama at Birmingham
Birmingham, AL

Randy Sweis, MD
Assistant Professor
University of Chicago
Chicago, IL
Faculty

Nizar M. Tannir, MD, FACP
Professor
MD Anderson Cancer Center
Houston, TX

Ulka Nitkin Vaishampayan, MBBS
University of Michigan
Ann Arbor, MI

Martin H. Voss, MD
Clinical Director, Genitourinary Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Christopher Weight, MD, MSc
Center Director Urologic Oncology
Cleveland Clinic
Cleveland, OH

Christopher G. Wood, MD, FACS
Professor and Deputy Chairman, Department of Urology
Division of Surgery
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Jeffrey Yorio, MD
Medical Oncologist
Texas Oncology - Central Austin,
US Oncology Research
Austin, TX

Tian Zhang, MD
Associate Professor
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
<table>
<thead>
<tr>
<th>POSTER NUMBER</th>
<th>TITLE</th>
<th>LEAD AUTHOR NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIP01</td>
<td>SWOG S1931 (PROBE): Phase III randomized trial of Immune checkpoint inhibitor (ICI) combination regimen with or without Cytoreductive Nephrectomy (CN) in Advanced Renal Cancer [NCT04510597]</td>
<td>Ulka Vaishampayan</td>
</tr>
<tr>
<td>TIP02</td>
<td>First-Line (1L) MK-1308A + Lenvatinib or Pembrolizumab + Belzutifan + Lenvatinib Versus Pembrolizumab + Lenvatinib for Clear Cell Renal Cell Carcinoma (ccRCC): A Randomized, Open-Label Phase 3 Study</td>
<td>Martin H. Voss</td>
</tr>
<tr>
<td>TIP03</td>
<td>Randomized, Open-Label, Phase 3 Study of Belzutifan Plus Lenvatinib Versus Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) After Anti–PD-1/PD-L1 Therapy</td>
<td>Robert Motzer</td>
</tr>
<tr>
<td>TIP04</td>
<td>Treatment of Advanced Renal Cell Carcinoma (RCC) After Progression on Systemic Therapy: Open-Label Phase 2 Study of Two Doses of the HIF-2α Inhibitor Belzutifan</td>
<td>Michael Atkins</td>
</tr>
<tr>
<td>TIP05</td>
<td>TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor</td>
<td>Toni Choueiri</td>
</tr>
<tr>
<td>TIP06</td>
<td>KEYNOTE-B61: An Open-Label Phase 2 Study of First-Line (1L) Pembrolizumab With Lenvatinib for Non–Clear Cell Renal Cell Carcinoma (nccRCC)</td>
<td>Chung-Han Lee</td>
</tr>
<tr>
<td>TIP07</td>
<td>Investigational Immune and Targeted Combination Therapies for Patients With Advanced Clear Cell Renal Cell Carcinoma (ccRCC): A Phase 1b/2 Umbrella Study</td>
<td>Laurence Albiges</td>
</tr>
<tr>
<td>TIP08</td>
<td>Optimal Treatment by Invoking biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)</td>
<td>Yu-Wei Chen</td>
</tr>
<tr>
<td>TIP09</td>
<td>89Zr-TLX250 for PET/CT Imaging of Clear Cell Kidney Cancer</td>
<td>Brian Shuch</td>
</tr>
<tr>
<td>TIP10</td>
<td>A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)</td>
<td>Rana R. McKay</td>
</tr>
<tr>
<td>CTR11</td>
<td>First-line nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) in patients with long-term survival of ≥5 years in the CheckMate 214 trial</td>
<td>Nizar M. Tannir</td>
</tr>
<tr>
<td>CTR12</td>
<td>Outcomes with first-line nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) and treatment-related adverse event (TRAEE) timing/management in CheckMate 9ER</td>
<td>Elizabeth R. Kessler</td>
</tr>
</tbody>
</table>
# Poster Listings

To view poster presentations during IKCS 2021, please visit the poster hall.

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Lead Author Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTR13</td>
<td>A prospective randomized pilot trial of stereotactic body radiation therapy vs. radiofrequency ablation for the management of small renal masses</td>
<td>Ani Kapoor</td>
</tr>
<tr>
<td>CTR14</td>
<td>Characterization and Management of Adverse Reactions (ARs) in Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Lenvatinib + Pembrolizumab (CLEAR Study)</td>
<td>Robert Motzer</td>
</tr>
<tr>
<td>CTR15</td>
<td>First results of 68Ga-EMP-100 PET for imaging c-MET expression in metastatic renal cell carcinoma</td>
<td>Lena Mittlmeier</td>
</tr>
<tr>
<td>N16</td>
<td>Anti-CAIX BBζ CAR4/8 T Cells Exhibit Superior Efficacy in a Clear Cell Renal Cell Carcinoma (ccRCC) Mouse Model</td>
<td>Yufei Wang</td>
</tr>
<tr>
<td>N17</td>
<td>Deconstructing the clear cell renal cell carcinoma using single nuclei multiomics</td>
<td>Michael P. Mariani</td>
</tr>
<tr>
<td>N18</td>
<td>Navigating multiomics in clear cell renal cell carcinoma-ccRCC: Network analyses on DNA methylation-5mC, DNA hydroxymethylation-5hmC, messenger RNA-mRNA, and microRNA-miRNA expression</td>
<td>Ze Zhang</td>
</tr>
<tr>
<td>N19</td>
<td>COVID-19 vaccination in patients with renal cell carcinoma receiving immune checkpoint inhibitors</td>
<td>Hannah Dzimitrowicz</td>
</tr>
<tr>
<td>N20</td>
<td>Radiation prior to combination-immunotherapy in patients with metastatic renal cell carcinoma (mRCC) and bone metastases.</td>
<td>Hesham Yasin</td>
</tr>
<tr>
<td>N21</td>
<td>Adverse Events (AE) Management among Advanced Renal Cell Carcinoma (aRCC) Patients Receiving First-Line (1L) Axitinib+Checkpoint Inhibitor (CPI) Therapy</td>
<td>Yousef Zakharia</td>
</tr>
<tr>
<td>N22</td>
<td>Nivolumab plus cabozantinib (N+C) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and bone metastasis: subgroup analysis of the Phase 3 CheckMate 9ER trial</td>
<td>Andrea Apolo</td>
</tr>
<tr>
<td>N23</td>
<td>Real-world clinical characteristics and treatment patterns of patients with advanced renal cell carcinoma treated with first-line avelumab+axitinib in the United States</td>
<td>Giovanni Zanotti</td>
</tr>
<tr>
<td>N24</td>
<td>Disease control rate (DCR) with tivozanib (TIVO) vs sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC</td>
<td>Sumanta Kumar Pal</td>
</tr>
<tr>
<td>N25</td>
<td>Cost per survivor (CPS) and cost per life-month (CPLM) of nivolumab plus ipilimumab (NIVO+IPI) versus pembrolizumab plus axitinib (PEMBRO+AXI) for previously untreated advanced renal cell carcinoma (aRCC)</td>
<td>Stephen Huo</td>
</tr>
</tbody>
</table>
## Poster Listings

**To view poster presentations during IKCS 2021, please visit the poster hall**

<table>
<thead>
<tr>
<th>POSTER NUMBER</th>
<th>TITLE</th>
<th>LEAD AUTHOR NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>N26</td>
<td>Gene expression profiling (GEP) of non-clear cell renal cell carcinoma (nccRCC) identifies a unique spectrum of transcriptional signatures with potential clinical relevance</td>
<td>Pedro Barata</td>
</tr>
<tr>
<td>N27</td>
<td>Spectral Dual-Layer Detector CT: A New Independent Prognostic Tool in Metastatic Renal Cell Carcinoma</td>
<td>Aska Drjjevic-Nielsen</td>
</tr>
<tr>
<td>N28</td>
<td>Direct Imaging Characteristics of Myeloid Derived Suppressor Cell (MDSC) Populations in Renal Cell Carcinoma Patients (RCC) by Ethnicity – An Exploratory Analysis</td>
<td>Arnab Basu</td>
</tr>
<tr>
<td>N29</td>
<td>Expression of Aberrant Splice Variants are Strongly Associated with Clinical Outcome in Clear Cell RCC</td>
<td>Andrew Chang</td>
</tr>
<tr>
<td>N30</td>
<td>Molecular profiling of metastatic renal cell carcinoma (mRCC) treated with ipilimumab-nivolumab (ipi-nivo)</td>
<td>Tian Zhang</td>
</tr>
<tr>
<td>N31</td>
<td>Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma</td>
<td>Priyanka V. Chablani</td>
</tr>
<tr>
<td>N32</td>
<td>Assessing human kidney cancer metabolism with intraoperative isotope tracing</td>
<td>Divya Bezwada</td>
</tr>
<tr>
<td>N33</td>
<td>Outcomes of Cytoreductive Nephrectomy Followed by Active Surveillance in Metastatic Renal Cell Carcinoma</td>
<td>Sari Khaleel</td>
</tr>
<tr>
<td>N34</td>
<td>BAPI Suppresses Tumor Growth Via Interferon Beta and ISGF3 in Clear Cell Renal Cell Carcinoma</td>
<td>Lauren Lanbein</td>
</tr>
<tr>
<td>N35</td>
<td>Machine learning predicts BAP1/PBRM1 from digital histology in clear cell Renal Cell Carcinoma: TRACERx Renal</td>
<td>Charlotte Spencer</td>
</tr>
<tr>
<td>N36</td>
<td>Adverse Radiologic and Pathologic Features Impact Survival Outcomes for Small Renal Masses Following Nephrectomy</td>
<td>Sari Khaleel</td>
</tr>
<tr>
<td>E37</td>
<td>Characterization of the tumor immune microenvironment in clear cell renal cell carcinoma (ccRCC): prognostic and therapeutic implications of an M0-macrophage enriched subtype</td>
<td>Mark Farha</td>
</tr>
<tr>
<td>E38</td>
<td>Disease Free Survival (DFS) as a Predictor of Overall Survival (OS) in Localized RCC following First Nephrectomy</td>
<td>Naomi B. Haas</td>
</tr>
<tr>
<td>E39</td>
<td>Conditional survival and 5-year follow-up in CheckMate 214: first-line nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) in advanced renal cell carcinoma (aRCC)</td>
<td>Hans J. Hammers</td>
</tr>
</tbody>
</table>
## Poster Listings

TO VIEW POSTER PRESENTATIONS DURING IKCS 2021, PLEASE VISIT THE POSTER HALL

<table>
<thead>
<tr>
<th>POSTER NUMBER</th>
<th>TITLE</th>
<th>LEAD AUTHOR NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>E40</td>
<td>First-line nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) by prior nephrectomy status in the CheckMate 9ER trial</td>
<td>Camillo Porta</td>
</tr>
<tr>
<td>E41</td>
<td>A phase 3 trial of lenvatinib plus pembrolizumab (LEN+PEMBRO) versus sunitinib as a first-line treatment for patients with advanced renal cell carcinoma (aRCC): overall survival follow-up analysis (CLEAR study)</td>
<td>Toni Choueiri</td>
</tr>
<tr>
<td>E42</td>
<td>Characterizing the immune response in patients with renal cell carcinoma (RCC) following COVID-19 vaccination</td>
<td>Jasnoor Malhotra</td>
</tr>
<tr>
<td>E43</td>
<td>Nivolumab plus Cabozantinib in Patients with Non-Clear Cell Renal Cell Carcinoma: Results of a Phase 2 Trial.</td>
<td>Chung-Han Lee</td>
</tr>
<tr>
<td>E44</td>
<td>Initial Management of Indeterminate Renal Masses in a Statewide Collaborative: a MUSIC-KIDNEY analysis</td>
<td>Mohit Butaney</td>
</tr>
<tr>
<td>E45</td>
<td>Documentation of Nephrometry Scores for cT1a Renal Masses Correlates with Avoidance of Radical Nephrectomy Across the MUSIC-KIDNEY Statewide QI Collaborative</td>
<td>Sara Perkins</td>
</tr>
<tr>
<td>E46</td>
<td>Building a roadmap for surveillance of renal masses: Results from MUSIC consensus panel</td>
<td>Amit Patel</td>
</tr>
<tr>
<td>LBA47</td>
<td>Molecular Dissection of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-Mesenchymal Transition Gene Expression Signature</td>
<td>Srinivas Nallandhighal</td>
</tr>
</tbody>
</table>

---

**KIDNEY CANCER ASSOCIATION’S DATA FEDERATION**

POWERED BY THE KCA THINK TANK

**COMING SOON!**
A new way to do multi-institutional research. Visit the Kidney Cancer Association booth to learn more.
IKCS: North America 2021
is Made Possible with the Generous Support of:

DIAMOND SPONSORS

EXELIXIS®
Pfizer Oncology

GOLD SPONSOR

Bristol Myers Squibb™

SILVER SPONSOR

Eisai

BRONZE SPONSORS

AVEO Oncology
Genentech
MERCK

GENERAL SPONSOR

NEKTAR®
See You in Antwerp, Belgium for 2022 IKCS: Europe

SAVE THE DATE
22 – 23 April 2022
In-person with virtual streaming

Learn more at KCAMEETINGS.ORG
The Kidney Cancer Association is a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education in order to be the universal leader in finding a cure for kidney cancer.

**DONATION ADDRESS**
Please send donations to our secure lock-box:
Kidney Cancer Association
PO Box 676226
Dallas, TX 75267-6226

**KIDNEYCANCER.ORG**
office@kidneycancer.org
800-850-9132
International: +1-847-332-1051

**MAILING ADDRESS**
Kidney Cancer Association
9450 SW Gemini Drive #38269
Beaverton, OR 97008-7105

**HEADQUARTERS**
Houston, Texas, USA

@KidneyCancer  |  #UnstoppableTogether